Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Discovery Grants Program - Individual

Carleton University

$15,000.00

Targeting nuclear receptors with novel synthetic ligands

EF 2009-10

Résumé
My proposal consists of three parts, all related to the general area of pharmaceutical drug design. Part I. Improving the calculation of the binding affinity of a drug to a protein target. Part II. Creating a complete set of agonists and antagonists for the estrogen receptor. Part III. Creating an improved form of "peptide patch" to block the activation of the estrogen receptor(s). Rationale: The estrogen receptors and the estrogens which activate them (including the female hormones estradiol and estrone) are essential for determining female sexual characteristics and help to prevent diseases such as bone loss, heart attack and stroke. After menopause estrogen levels drop by 90% and women become prone to these diseases as well as suffering from other symptoms such as hot flashes. Thus, until recently, and still to a significant extent, many women after menopause began a regime of estrogen supplementation known as hormone replacement therapy (HRT). However, epidemiological data have shown that long-term HRT usage leads to an increased risk of breast and uterine cancers. The projects described in this proposal are aimed at creating safer drugs for HRT. They will also help to understand how cancers develop, particularly breast cancer, and how they can be controlled with the new compounds we are trying to develop.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
6580-2009
Name nom
Wright, James
Department département
Chemistry
Organization id
23
Institution établissement
Carleton University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2009
Competition year année de concours
2009
Award amount
15000
Program id
RGPIN
Program nane en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
24
Committee name en
Inorganic & Organic Chemistry
Committee name fr
Chimie inorg. et org.
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
5300
Research subject group en
Molecular biology
Research subject group fr
Biologie moléculaire
Research subject en
Molecular biology
Research subject fr
Biologie moléculaire
Partie
1
Nb partie
1
Application title
Targeting nuclear receptors with novel synthetic ligands
Keyword
NA
Application summary
My proposal consists of three parts, all related to the general area of pharmaceutical drug design. Part I. Improving the calculation of the binding affinity of a drug to a protein target. Part II. Creating a complete set of agonists and antagonists for the estrogen receptor. Part III. Creating an improved form of "peptide patch" to block the activation of the estrogen receptor(s). Rationale: The estrogen receptors and the estrogens which activate them (including the female hormones estradiol and estrone) are essential for determining female sexual characteristics and help to prevent diseases such as bone loss, heart attack and stroke. After menopause estrogen levels drop by 90% and women become prone to these diseases as well as suffering from other symptoms such as hot flashes. Thus, until recently, and still to a significant extent, many women after menopause began a regime of estrogen supplementation known as hormone replacement therapy (HRT). However, epidemiological data have shown that long-term HRT usage leads to an increased risk of breast and uterine cancers. The projects described in this proposal are aimed at creating safer drugs for HRT. They will also help to understand how cancers develop, particularly breast cancer, and how they can be controlled with the new compounds we are trying to develop.